Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics, Inc. (NASDAQ: PTCT) is a global biopharmaceutical company focused on clinically differentiated medicines for children and adults living with rare disorders. The PTCT news feed on Stock Titan aggregates company announcements, financial updates and regulatory milestones that PTC discloses through press releases and SEC filings.
Investors following PTCT news can see updates on the commercial performance and global rollout of products such as Sephience (sepiapterin) for phenylketonuria (PKU), as well as revenue contributions from the company’s Duchenne muscular dystrophy franchise, which includes Translarna (ataluren) and Emflaza (deflazacort). News items also cover royalty revenue from Evrysdi (risdiplam) and changes in royalty arrangements, such as the sale of certain Evrysdi royalty rights to Royalty Pharma.
PTC Therapeutics regularly reports quarterly and annual financial results, including total revenue, product revenue, royalty and collaboration revenue, and details on GAAP and non-GAAP R&D and SG&A expenses. Corporate updates often highlight pipeline and regulatory developments, including FDA meetings for programs like votoplam in Huntington’s disease and vatiquinone in Friedreich’s ataxia, as well as ongoing review of the Translarna NDA.
The company also issues news about regulatory approvals and launches in different regions, such as Sephience approvals in the EU, US and Japan, and about R&D-focused events and investor conference presentations. In addition, PTC discloses equity inducement grants under Nasdaq Listing Rule 5635(c)(4), illustrating its use of stock options and restricted stock units as part of employee compensation.
By monitoring the PTCT news page, readers can track how product launches, regulatory decisions, collaborations, royalty transactions and capital markets activities shape the company’s progress in the rare disease biopharmaceutical sector.
PTC Therapeutics (NASDAQ: PTCT) released new data confirming the clinical benefits of EMFLAZA® (deflazacort) for Duchenne muscular dystrophy (DMD) patients over prednisone. The pooled results showed significant improvement in physical performance metrics, including the six-minute walk test and the North Star Ambulatory Assessment. Experts emphasized the advantages of early EMFLAZA initiation for better patient outcomes. The data also highlighted real-world evidence of EMFLAZA's effectiveness and its role in slowing disease progression in DMD patients.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced the approval of Evrysdi™ (risdiplam) in Japan for treating spinal muscular atrophy (SMA). This approval, based on pivotal studies in infants and adults, will trigger a $10M milestone payment from Roche. Evrysdi provides an at-home oral treatment option, enhancing accessibility for patients. It has previously gained FDA and EMA approvals for patients aged 2 months and older. SMA, a severe neuromuscular disease, affects approximately 1 in 10,000 babies, making this development significant for patient care.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced on June 11, 2021, the approval of non-statutory stock options for 118,350 shares and 30,835 restricted stock units (RSUs) to 66 new employees. These grants are part of the employment compensation to attract talent under NASDAQ's inducement grant exception. The stock options have an exercise price of $42.95 and vest over four years, while RSUs vest annually. This initiative aims to enhance PTC's workforce as it focuses on developing innovative treatments for rare disorders, supporting its growth strategy and commitment to patient care.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced positive interim results from the RAINBOWFISH trial, showing that pre-symptomatic infants with spinal muscular atrophy (SMA) achieved significant motor milestones after treatment with Evrysdi. These milestones include sitting, rolling, crawling, standing, and walking independently. Additionally, interim results from the JEWELFISH safety study show stabilization in motor function and increased SMN protein levels. Evrysdi is FDA-approved for SMA patients aged 2 months and older and is marketed by Genentech.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced the election of Mary L. Smith to its Board of Directors on June 9, 2021. Smith brings extensive experience from her role as Principal Deputy Director at the Indian Health Service, where she oversaw a $6 billion healthcare division. Currently, she serves as Vice Chair at VENG Group, advising on business strategy and healthcare governance. Smith aims to leverage her background to support PTC's mission in advancing its pipeline of medicines for rare diseases. CEO Stuart W. Peltz emphasized her valuable insights for the company's growth.
PTC Therapeutics announced that the FDA and European Commission have granted Orphan Drug Designation (ODD) for PTC923, aimed at treating hyperphenylalaninemia, primarily caused by Phenylketonuria (PKU). PKU can lead to severe cognitive disabilities and seizures. PTC923, an oral synthetic sepiapterin, is expected to enter a Phase 3 trial, APHENITY, in mid-2021. ODD provides various benefits, including grant funding, tax advantages, and potential market exclusivity in both the U.S. and EU.
PTC Therapeutics, based in South Plainfield, N.J., will present a company overview at the William Blair 41st Annual Growth Stock Conference on June 2, 2021, at 3:40 p.m. ET. The presentation will be accessible via a live webcast on their website and available for archiving for 30 days post-event. PTC is dedicated to developing innovative treatments for rare disorders and emphasizes maximizing patient access to its medicines.
PTC Therapeutics, Inc. (NASDAQ: PTCT) revealed findings on the impact of caring for children with aromatic L-Amino acid decarboxylase deficiency (AADC-d) at the Virtual ISPOR North America 2021 Conference. The study highlights that caregivers dedicate an average of 105 hours weekly to support, often leading 75% to leave jobs or reduce hours. The findings underscore the critical need for effective treatments, as AADC-d causes severe disabilities and requires constant care. Data also show a positive correlation between treatment efficacy and improved health outcomes for affected children.
PTC Therapeutics (PTCT) reported a strong Q1 2021 with total revenues of $117.9 million, a 32% increase from Q1 2020. The Duchenne muscular dystrophy (DMD) franchise revenue reached $90 million, driven by new patient uptake and geographic expansion. Preliminary results from the PTC518 trial showed a positive dose-dependent reduction in Huntington mRNA. However, the net loss for Q1 2021 was $128.6 million, compared to $112.7 million a year earlier. PTC reaffirms its 2021 guidance, projecting DMD net product revenues between $355 and $375 million.
PTC Therapeutics (NASDAQ: PTCT) has announced its participation in several upcoming virtual investor conferences. The presentations include:
- BofA Securities 2021 Virtual Health Care Conference on May 11 at 8:45 a.m. ET
- 2021 RBC Capital Markets Global Healthcare Virtual Conference on May 18 at 10:20 a.m. ET
- 2021 UBS Global Healthcare Virtual Conference on May 26 at 12:00 p.m. ET
These presentations will be available live and archived on PTC's investor relations website for 30 days.